Literature DB >> 1660716

Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia.

C Ferri1, F Greco, G Longombardo, P Palla, A Moretti, E Marzo, P V Fosella, G Pasero, S Bombardieri.   

Abstract

The prevalence of antibodies to hepatitis C virus (HCVAb) was investigated in 52 unselected patients with mixed cryoglobulinemia and in 84 patients with other systemic immunologic diseases. HCVAb were detected by an enzyme-linked immunosorbent assay, and their specificity was evaluated by a recombinant-based immunoblot assay. The presence of HBV-related markers was investigated in the same samples. HCVAb were found in 54% of mixed cryoglobulinemia patients, and the finding was confirmed by recombinant-based immunoblot assay in all cases. HCVAb and/or HBV markers were present in 70% of the patients. HCVAb seropositivity was significantly more frequent in mixed cryoglobulinemia patients with biopsy-proven liver involvement (P less than 0.01) and with increased serum transaminase levels (P less than 0.01). HCVAb were virtually absent in control patients with other immunologic diseases. These results support the notion that viral agents, i.e., HCV and possibly HBV, have a role in the pathogenesis of mixed cryoglobulinemia patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660716     DOI: 10.1002/art.1780341221

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  45 in total

Review 1.  Hepatitis C virus infection and lymphoproliferative disorders.

Authors:  L R Peña; S Nand; N De Maria; D H Van Thiel
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

2.  Hepatitis C: a possible etiology for cryoglobulinaemia type II.

Authors:  A Pechère-Bertschi; L Perrin; P de Saussure; J J Widmann; E Giostra; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

3.  Is interferon alpha 2b effective on cryoglobulinaemia related to hepatitis C virus?

Authors:  B Taillan; E Ferrari; A Pesce; G Garnier; H Vinti; J G Fuzibet; P Dujardin
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

Review 4.  Mixed cryoglobulinemia as a model of systemic vasculitis.

Authors:  F Dammacco; D Sansonno
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

5.  Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients.

Authors:  C Ferri; A L Zignego; G Longombardo; M Monti; L La Civita; F Lombardini; F Greco; A Mazzoni; G Pasero; P Gentilini
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

6.  Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study.

Authors:  R Caporali; C Montecucco; O Epis; F Bobbio-Pallavicini; T Maio; M A Cimmino
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

7.  Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia.

Authors:  A Gabrielli; A Manzin; M Candela; M L Caniglia; S Paolucci; M G Danieli; M Clementi
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Peripheral neuropathy associated with essential mixed cryoglobulinaemia: a role for hepatitis C virus infection?

Authors:  E Apartis; J M Léger; L Musset; M Gugenheim; P Cacoub; O Lyon-Caen; C Pierrot-Deseilligny; J J Hauw; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

9.  Parvovirus B19 infection, hepatitis C virus infection, and mixed cryoglobulinaemia.

Authors:  P Cacoub; N Boukli; P Hausfater; A Garbarg-Chenon; P Ghillani; V Thibault; L Musset; J M Huraux; J C Piette
Journal:  Ann Rheum Dis       Date:  1998-07       Impact factor: 19.103

10.  Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia.

Authors:  D Sansonno; G Lauletta; L Nisi; P Gatti; F Pesola; N Pansini; F Dammacco
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.